Incidence, Risk Factors, and Management of Adverse Events in Contemporary, Real‐World Care of Children With Juvenile Idiopathic Arthritis
OBJECTIVE: We describe the frequency, risk factors, severity, and management of actionable and serious adverse events (AAEs and SAEs) in children with newly diagnosed juvenile idiopathic arthritis (JIA) in Canada. METHODS: We enrolled patients within three months of JIA diagnosis in the Canadian Alliance of Pediatric Rheumatology Investigators (CAPRI) Registry, an ongoing prospective, registry-based cohort study. At every clinic visit, clinicians reported AAEs since the previous visit, their severity, and actions undertaken. We calculated proportion of patients and visits with an event, events rates per 100 patient years (PY), and used Kaplan-Meier and Cox regression analysis to estimate first AAE risk and assess associated risk factors. RESULTS: Among 964 patients followed for 2,046 PY, AAEs occurred in 39.0% of patients (34.9 per 100 PY) and SAEs in 3.4% (2.0 per 100 PY). Gastrointestinal symptoms linked to nonsteroidal anti-inflammatory drugs (NSAIDs) and methotrexate (MTX) were most common (56.4%). In adjusted analyses, active disease, subcutaneous MTX (hazard ratio [HR] 3.27, P < 0.001), oral MTX (HR 2.08, P < 0.001), and NSAIDs (HR 2.17, P < 0.001) were associated with increased AAE risk, whereas biologic disease-modifying antirheumatic drugs (bDMARDs) were associated with decreased risk (HR 0.46, P < 0.001). Forty SAEs occurred, including 16 infections with hospitalization and one malignancy, mostly in patients not receiving bDMARDs. There were no deaths, demyelinating conditions, or opportunistic infections. CONCLUSION: In this real-practice JIA cohort, AAEs were reported in 2 of 5 patients, and most were mild events related to NSAIDs and MTX. SAEs were rare with no deaths and few major complications.
Authors
- Adam M. Huber (ORCID: https://orcid.org/0000-0002-6616-1689)
- Gilles Boire (ORCID: https://orcid.org/0000-0003-2481-5821)
- Roberta Audrey Berard (ORCID: https://orcid.org/0000-0003-2780-0617)
- Gaëlle Chédeville (ORCID: https://orcid.org/0000-0001-9702-7776)
- Michelle Batthish (ORCID: https://orcid.org/0000-0001-6412-1029)
- Heinrike Schmeling (ORCID: https://orcid.org/0000-0001-8142-8946)
- Dax G. Rumsey (ORCID: https://orcid.org/0000-0002-9211-4640)
- Jaime Guzmán (ORCID: https://orcid.org/0000-0001-8977-2581)
- Jean‐Philippe Proulx‐Gauthier (ORCID: https://orcid.org/0009-0000-0972-3502)
- Bashayer Alnuaimi (ORCID: https://orcid.org/0009-0004-6804-7187)
- The CAPRI Registry Investigators
- Bashayer Alnuaimi
- Gilles Boire
Institutions
- Western University (CA)
- Dalhousie University (CA)
- Université de Sherbrooke (CA)
- University of British Columbia (CA)
- University of Alberta (CA)
- University of Calgary (CA)
- London Health Sciences Centre (CA)
- McGill University Health Centre (CA)
- Centre hospitalier universitaire de Québec (CA)
- Children's Hospital of Western Ontario (CA)
- Université Laval (CA)
- McGill University (CA)
- McMaster University (CA)
Publication Details
- Journal
- Arthritis Care & Research
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1002/acr.80162
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00